INTRODUCTION {#s1}
============

Esophageal cancer is the sixth leading cause of cancer-related mortality and the eighth most common cancer worldwide \[[@R1]\]. An estimated 455,800 new esophageal cancer cases and 400,200 deaths occurred in 2012 worldwide \[[@R2]\]. The two major types are esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EADC). Smoking and drinking are well-known environmental risk factors for ESCC, whereas obesity and chronic gastroesophageal refluxing are main EADC risk factors. However, only a subset of individuals exposed to those environmental risk factors develop EC, suggesting a role of host susceptibility factors. Some studies have suggested that genetic polymorphisms might explain individual differences in susceptibility to esophageal cancer \[[@R3], [@R4]\].

Glutathione-S-transferases (GSTs) are important phase II biotransformation enzymes that catalyzing the nucleophilic addition of glutathione to several hazardous xenobiotics, including phase I electrophilic and carcinogenic metabolites \[[@R5]\]. However, these enzymes can also activate certain chemicals that target cellular proteins and DNA to elicit detrimental carcinogenic effects through genotoxic and non-genotoxic mechanisms. One of important enzymes in GSTs family is GSTT1. GSTT1 is genetically polymorphic, and deletion polymorphism of the GSTT1 loci (null genotype) results in the loss of functional activity. Several studies have found that GSTT1 null genotype is strongly associated with susceptibility to a number of cancers, such as colorectal, renal and oral cancers *et al.* \[[@R6]--[@R8]\]. Previous studies have been published to estimate the association between GSTT1 null genotype and the risk of esophageal cancer, but the results are inconsistent \[[@R9]--[@R11]\].

To date, several meta-analysis studies have reported the association between null GSTT1 genotype and the risk of esophageal cancer. However, the results of these studies remain outdated and incomprehensive \[[@R12]--[@R14]\]. In the last 4 years, many case-control studies were published to estimate this association. Thus, to obtain a conclusive result about this association, we performed current meta-analysis that includes all recent publications to review and summarize the association between the GSTT1 polymorphism and the risk of esophageal cancer.

RESULTS {#s2}
=======

Characteristics {#s2_1}
---------------

In total, 100 articles were retrieved. Figure [1](#F1){ref-type="fig"} summarized the selecting process. Finally, a total of 30 studies with 4482 cases and 6681 controls met the inclusion criteria \[[@R9]--[@R11], [@R15]--[@R41]\]. Among them, 18 were from Asians, 10 were from Caucasians, and 2 were from Africans. There were 21 studies focused on the risk of ESCC with 3272 cases and 5535 controls, and 8 studies focused on the risk of EADC with 646 cases and 1908 controls. Characteristics of included studies and the distribution of GSTT1 polymorphism are summarized in Table [1](#T1){ref-type="table"} and Table [2](#T2){ref-type="table"}, respectively.

![Flow chart shows studies included procedure for meta-analysis](oncotarget-09-15111-g001){#F1}

###### Characteristics of the individual studies included in the meta-analysis

  Study              Year   Country        Ethnicity   Sample size   Genotype method
  ------------------ ------ -------------- ----------- ------------- -----------------
  Makhdoomi MA       2014   India          Asian       492/492       multiplex PCR
  Sharma A           2013   India          Asian       315/436       multiplex PCR
  Dura P             2013   Netherlands    Caucasian   432/591       PCR
  Talukdar FR        2013   India          Asian       112/130       PCR
  Zhang L            2013   China          Asian       138/170       PCR
  Djansugurova LB    2013   Kazakhstan     Caucasian   107/96        PCR
  Gao P              2012   China          Asian       40/80         PCR
  Matejcic M         2011   South Africa   African     528/876       PCR
  Malik MA           2010   India          Asian       135/195       multiplex PCR
  Li D               2010   South Africa   African     238/280       PCR
  Moaven O           2010   Iran           Asian       148/136       PCR
  Liu R              2010   China          Asian       97/97         multiplex PCR
  Ji R               2010   China          Asian       189/216       multiplex PCR
  Zendehdel K        2009   Sweden         Caucasian   172/470       multiplex PCR
  Zhang WL           2009   China          Asian       88/72         PCR
  Deng J             2008   China          Asian       87/162        PCR
  Rossini A          2007   Brazil         Caucasian   125/252       multiplex PCR
  Wideroff L         2007   USA            Caucasian   67/208        PCR
  Casson AG          2006   Canada         Caucasian   56/95         multiplex PCR
  Jain M             2006   India          Asian       100/137       multiplex PCR
  Yin LH             2005   China          Asian       106/106       PCR
  Roth MJ            2004   China          Asian       131/454       PCR
  Abbas A            2004   French         Caucasian   70/115        multiplex PCR
  Wang LD            2003   China          Asian       62/38         multiplex PCR
  Casson AG          2003   Canada         Caucasian   45/45         multiplex PCR
  Ribeiro Pinto LF   2003   Brazil         Caucasian   32/67         PCR
  Gao CM             2002   China          Asian       141/223       multiplex PCR
  Tan W              2000   China          Asian       150/150       multiplex PCR
  van Lieshout EM    1999   Netherlands    Caucasian   34/247        PCR
  Lin DX             1998   China          Asian       45/45         multiplex PCR

###### Distribution of GSTT1 null genotype among cases and controls

  Study             Year   Control   EC    ESCC   EADC                     
  ----------------- ------ --------- ----- ------ ------ ----- ----- ----- ----
  Makhdoomi MA      2014   367       125   306    186    306   186   /     /
  Sharma A          2013   373       63    233    82     233   82    /     /
  Dura P            2013   463       128   335    97     87    18    248   79
  Talukdar FR       2013   92        38    66     46     66    46    /     /
  Zhang L           2013   90        80    62     76     62    76    /     /
  Djansugurova LB   2013   35        61    19     88     19    88    /     /
  Gao P             2012   55        25    18     22     18    22    /     /
  Matejcic M        2011   648       228   375    153    375   153   /     /
  Malik MA          2010   146       49    110    25     /     /     /     /
  Li D              2010   178       102   125    113    125   113   /     /
  Moaven O          2010   105       31    112    36     112   36    /     /
  Liu R             2010   57        40    34     63     34    63    /     /
  Ji R              2010   122       94    91     98     91    98    /     /
  Zendehdel K       2009   394       76    150    22     70    7     80    15
  Zhang LW          2009   39        33    31     57     31    57    /     /
  Deng J            2008   75        87    36     51     /     /     /     /
  Rossini A         2007   192       60    110    15     110   15    /     /
  Wideroff L        2007   173       35    59     8      /     /     59    8
  Casson AG         2006   80        15    42     14     /     /     42    14
  Jain M            2006   100       37    72     28     56    20    6     3
  Yin LH            2005   55        51    60     46     /     /     /     /
  Roth MJ           2004   211       243   54     77     54    77    /     /
  Abbas A           2004   85        30    56     14     31    13    25    1
  Wang LD           2003   18        20    28     34     25    34    /     /
  Casson AG         2003   33        12    37     8      /     /     37    8
  Rebeiro           2003   52        15    26     6      /     /     /     /
  Gao CM            2002   104       119   67     74     /     /     /     /
  Tan W             2000   91        59    90     60     90    60    /     /
  van Lieshout EM   1999   198       49    28     6      11    2     17    4
  Lin DX            1998   22        23    26     19     /     /     /     /

Abbreviations: EC: esophageal cancer; ESCC: esophageal squamous cell carcinoma; EADC: esophageal adenocarcinoma.

Quantitative synthesis {#s2_2}
----------------------

Table [3](#T3){ref-type="table"} showed the main result of the association between GSTT1 null genotype and the risk of esophageal cancer. Overall, there was a significant correlation of GSTT1 null genotype with esophageal cancer risk (OR = 1.20; 95% CI 1.04--1.40; *P* \< 0.05; Table [3](#T3){ref-type="table"} and Figure [2](#F2){ref-type="fig"}). In a subgroup analysis by ethnicity, GSTT1 null genotype was correlated with a significantly increased risk of esophageal cancer among Asians (OR = 1.33; 95% CI 1.12--1.58; *P* \< 0.05; Table [3](#T3){ref-type="table"} and Figure [2](#F2){ref-type="fig"}), but not among Caucasians and Africans (OR = 0.91; 95% CI 0.65--1.26; *P* \> 0.05 for Caucasians and OR = 1.32; 95% CI 0.98--1.77; *P* \> 0.05 for Africans; Table [3](#T3){ref-type="table"} and Figure [2](#F2){ref-type="fig"}).

###### Meta-analysis of the GSTT1 null genotype and esophageal cancer risk

                Number of Study   OR (95%CI)          *P*     *P* (*Q*-test)   I-squared
  ------------- ----------------- ------------------- ------- ---------------- -----------
  Total         30                1.20 (1.04--1.40)   0.014   0.000            60.2
  Ethnicity                                                                    
   Asians       18                1.33 (1.12--1.58)   0.001   0.003            54.9
   Caucasians   10                0.91 (0.65--1.26)   0.569   0.01             58.3
   Africans     2                 1.32 (0.98--1.77)   0.070   0.157            50.0
  ESCC          21                1.34 (1.12--1.61)   0.001   0.000            62.6
  Ethnicity                                                                    
   Asians       13                1.54 (1.30--1.82)   0.000   0.097            35.7
   Caucasians   6                 0.87 (0.48--1.57)   0.640   0.002            73.5
   Africans     2                 1.32 (0.98--1.77)   0.070   0.157            50.0
  EADC          8                 0.98 (0.71--1.35)   0.911   0.240            23.7

![Forest plot of the association of GSTT1 null genotype with esophageal cancer risk](oncotarget-09-15111-g002){#F2}

In the analysis by histological type, GSTT1 null genotype were correlated with a significantly increased risk of ESCC (OR = 1.34; 95% CI 1.12--1.61; *P* \< 0.05; Table [3](#T3){ref-type="table"} and Figure [3](#F3){ref-type="fig"}). Moreover, in a subgroup analysis by ethnicity, GSTT1 null genotype was correlated with a significantly increased risk of ESCC among Asians (OR = 1.54; 95% CI 1.30--1.82; *P* \< 0.05; Table [3](#T3){ref-type="table"} and Figure [3](#F3){ref-type="fig"}), but not among Caucasians and Africans (OR = 0.87; 95% CI 0.48--1.57; *P* \> 0.05 for Caucasians and OR = 1.32; 95% CI 0.98--1.77; *P* \> 0.05 for Africans; Table [3](#T3){ref-type="table"} and Figure [3](#F3){ref-type="fig"}). In addition, there is no significant correlation of GSTT1 null genotype with the risk of EADC (OR = 0.98; 95% CI 0.71--1.35; *P* \> 0.05; Table [3](#T3){ref-type="table"} and Figure [4](#F4){ref-type="fig"}).
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![Forest plot of the association of GSTT1 null genotype with esophageal adenocarcinoma risk](oncotarget-09-15111-g004){#F4}

Test for publication bias, sensitivity analyses, and heterogeneity {#s2_3}
------------------------------------------------------------------

Publication bias was assessed by both the Begg's funnel plot and the Egger's test. The shape of the Begg's funnel plot did not reveal any evidence of obvious asymmetry (Figure [5](#F5){ref-type="fig"}). Egger's test further suggested no evidence of publication bias (*P* = 0.210). Thus, there was no obvious publication bias in this meta-analysis.

![Begg\'s funnel plot analysis of GSTT1 polymorphism with esophageal cancer risk](oncotarget-09-15111-g005){#F5}

The sensitivity analysis was conducted to test the influence of an individual data on the pooled ORs and CIs by eliding a study in turn. Our findings suggested that the present meta-analysis results were relatively robust and stable (Figure [6](#F6){ref-type="fig"}).

![One-way sensitivity analysis of GSTT1 polymorphism with esophageal cancer risk](oncotarget-09-15111-g006){#F6}

As showed in Figure [2](#F2){ref-type="fig"} and Figure [3](#F3){ref-type="fig"}, heterogeneity was significant in overall and in some subgroups. Thus, we measured the sources of heterogeneity by subgroup analysis. The results showed that Caucasians may lead to the major source of heterogeneity.

DISCUSSION {#s3}
==========

Many studies suggest genetic variants play important roles in individual susceptibility to esophageal cancer \[[@R3], [@R42]\]. In decades, epidemiological studies have been performed to assess the association of GSTT1 null genotype with the risk of esophageal cancer. However, the results were inconsistent \[[@R34], [@R36]\]. Previous meta-analyses also investigated the association \[[@R12]--[@R14]\], the findings should be interpreted with very cautions. In Weng *et al.* study, 11 studies included in the meta-analysis were in Chinese Han population. Although the results showed a significant association between GSTT1 null genotype and esophageal cancer risk, the single Chinese Han population limited the power of the statistical analysis \[[@R12]\]. Also In Yi *et al.* study, 15 studies included in the meta-analysis were in Asian population. Although the results showed a significant association between GSTT1 null genotype and esophageal cancer risk, the single Asian population limited the power of the statistical analysis \[[@R13]\]. In Cai *et al.* study, a total of 24 studies were used. Adjusted ORs with corresponding 95% CIs were reported in 9 studies. In the overall analysis there was no significant association between GSTT1 null genotype and esophageal cancer risk. However, meta-analysis of adjusted ORs showed a significant association between GSTT1 null genotype and esophageal cancer risk \[[@R14]\]. Because of the lack of available data, subgroup analysis by histological type was not performed in these studies \[[@R12]--[@R14]\]. Thus we conducted a comprehensive meta-analysis, to investigate not only the strength of association between GSTT1 null genotype and the risk of esophageal cancer, but also the association of GSTT1 null genotype with the risk of different histological types.

This meta-analysis, including 30 case-control studies with 4482 cases and 6681 controls, identified the association between GSTT1 null genotype and esophageal cancer risk. GSTT1 null genotype significantly increased overall esophageal cancer risk. In a subgroup analysis by ethnicity, GSTT1 null genotype was correlated with a significantly increased risk of esophageal cancer among Asians. In the analysis by histological type, GSTT1 null genotype was correlated with a significantly increased risk of ESCC, particularly in Asians. However, there was no significant correlation of GSTT1 null genotype with the risk of EADC. To date, this is the first meta-analysis concerning the association of GSTT1 null genotype with the risk of different histological types.

GSTT1, encodes an enzyme that plays a crucial role in the detoxification of a variety of endogenous or exogenous carcinogens. It is located on 22q11.23 with 8146 base pairs, 5 exons and 4 introns in all \[[@R5]\]. GSTT1 is genetically polymorphic, and GSTT1 null genotype results in the loss of functional activity \[[@R12]\]. Our results demonstrated that GSTT1 null genotype significantly increased overall esophageal cancer risk.

Since the results from meta-analysis can be affected by histological types, a subgroup analysis was carried out regarding different histological type for the GSTT1 null genotype. GSTT1 null genotype was correlated with a significantly increased risk of ESCC among Asians, but not among Caucasians and Africans. However, there was no significant correlation of GSTT1 null genotype with the risk of EADC. All results should be interpreted with caution. Only two African studies were recruited in the current meta-analysis, which may restrict statistical power to detect a real assessment in Africans. More large scale studies are needed to verify the results. Subgroup analyses were also performed regarding ethnicity for the GSTT1 null genotype. GSTT1 null genotype was correlated with a significantly increased risk of esophageal cancer among Asians, but not among Caucasians and Africans. The results were more robust on histological type of ESCC. This meta-analysis confirmed the mutual effect of GSTT1 null genotype in different populations to the risk of esophageal cancer. Possible explanations include: (1) significance of these enzymes may vary with the ethnicity genetic backgrounds, environmental exposures and histological types. The regional difference in the frequency of esophageal cancer is probably due to genetic polymorphism and variable exposure to environmental factors; (2) GSTs metabolize a variety of overlapping substrates and individuals lacking GSTT1 can also metabolize the carcinogens by other alternative GST enzymes. Furthermore, there was only one study concerning the association between GSTT1 null genotype and EADC on Asians. Thus, we failed to evaluate the potential role of GSTT1 null genotype in EADC risk in Asians due to the lack of available data to date. More case-control studies on the GSTT1 null genotype are encouraged, especially in Asians, for a better understanding the role of GSTT1 null genotype in the EADC development.

Some limitations must be acknowledged in the current meta-analysis. First, significant heterogeneity was observed between publications for GSTT1 null genotype. Potential sources of heterogeneity include the study design, publication year, ethnicity, country, histological type, sample size, and so on. When subgroup analyses were carried out according to ethnicity and histological type, this heterogeneity was reduced or removed in some subgroups, implying different effects on histological types and ethnic populations. These findings should be interpreted with very cautions. Second, our findings were based on unadjusted ORs and CIs, whereas a more precisely investigation could be performed if the sufficient individual data were available. Third, only two African studies were recruited in the current meta-analysis, the results in African population should be interpreted with caution. More large scale studies are needed to verify the results in Africans. Finally, due to lack of uniform individual-level data, further stratified analysis to measure any interactions between gene--gene variation and gene-metabolic traits was not performed.

In conclusion, our meta-analysis findings demonstrated that GSTT1 null genotype significantly increased esophageal cancer risk, particularly in Asians. In addition, GSTT1 null genotype was correlated with a significantly increased risk of ESCC, particularly among Asians. However, more studies are warranted to confirm or refute these correlations, particularly with respect to gene-gene and gene-environment interactions.

MATERIALS AND METHODS {#s4}
=====================

Study selection {#s4_1}
---------------

Pubmed, Embase, China National Knowledge Infrastructure (CNKI) and Wanfang databases (the search was updated in March 31, 2017) were searched using the following terms: 'glutathione S-transferase T1' or 'GSTT1', 'polymorphism' or 'variant', and 'esophageal' or 'esophagus', and 'cancer' or 'carcinoma' or 'tumor' or 'malignancy'. The literature search was limited to English or Chinese articles. Additional publications were identified by a manual search based on references of retrieved studied or reviews.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

The selection criteria were: (1) in a case-control study design, (2) studies that evaluated the relationship between the GSTT1 null genotype polymorphism and esophageal cancer, (3) usable data on genotype frequency. Thus, reports without usable data, reviews, comments and duplicated publications were excluded.

Data extraction {#s4_3}
---------------

The data were collected by two independent reviewers. The extracted information contained: first author, year of publication, country of origin, ethnicity, number of cases and controls, genotyping method and characteristics of cases and controls. When come to conflicting assessment, disagreements were settled through a discussion among all authors.

Statistical analysis {#s4_4}
--------------------

The strength of correlation between GSTT1 null genotype and the susceptibility of esophageal cancer was assessed by the crude odds ratios (ORs) with 95% confidence intervals (CIs). A *P* \< 0.05 (two-tailed) was considered as statistical significance. A Chi-square-based *I*^*2*^ test was used to detect heterogeneity \[[@R43]\] and an *I*^*2*^ \< 25% indicates low heterogeneity, 25% ≤ *I*^*2*^ ≤ 50% indicates moderate heterogeneity, and *I*^*2*^ \> 50% indicates large heterogeneity \[[@R44]\]. When *I*^*2*^ \> 50% or *P* \< 0.10 (two-sided), the random-effects model (the DerSimonian-Laird method) was utilized to pool the data \[[@R45]\], otherwise the fixed-effects model (the Mantel-Haenszel method) was used \[[@R46]\]. Subgourp analyses were conducted according to different ethnicity to identify the specific effects of heterogeneity. Publication bias was assessed by Begg's funnel plot and Egger's test \[[@R47]\]. Sensitivity analyses were conducted by one-way method. All statistical analyses were performed using STATA version 12.0 software (Stata Corporation, College Station, TX, USA).
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